GlassScriptPhysician profile
Michael T Spooner
NPI 1225018013
$7,096.77
in general payments reported to CMS, 2019-2025
26 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $758 · 2020: $538 · 2021: $819 · 2022: $715 · 2023: $1,159 · 2024: $1,708 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,026 · Travel and Lodging: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,026.20 |
| Travel and Lodging | $240.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,463.65 | 2020-2025 | Rhythmia Mapping System, Watchman Flx, General - Brady |
| Biosense Webster, INC. | $1,210.18 | 2020-2025 | Carto 3, Qdot Micro, Nuvision Ice Catheter |
| Abbott Laboratories | $1,136.06 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $837.22 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $369.41 | 2019 | |
| Medtronic, INC. | $248.00 | 2021-2023 | Linq II |
| Impulse Dynamics (USA) INC. | $243.88 | 2023-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $223.72 | 2024-2025 | Camzyos, Eliquis |
| Atricure, INC. | $220.91 | 2020-2023 | |
| Abiomed | $178.37 | 2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $161.44 | 2021-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $136.16 | 2022-2024 | Xarelto |
| Pfizer INC. | $123.00 | 2019 | |
| Irhythm Technologies, INC. | $103.03 | 2021-2022 | |
| Philips North America LLC | $91.21 | 2023-2025 | Mechanical Tools |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.91 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.68 | 2023-2025 | Jardiance |
| Cardiovascular Systems INC. | $37.12 | 2020 | |
| Teleflex LLC | $36.95 | 2023-2025 | Supercross, Turnpike |
| Merck Sharp & Dohme LLC | $36.13 | 2025 | Verquvo |
| Bridgebio Pharma, INC. | $33.10 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $28.04 | 2023 | Inpefa |
| Novo Nordisk INC | $16.78 | 2025 | Wegovy |
| Convatec INC. | $14.47 | 2025 | |
| Bracco Diagnostics INC. | $13.79 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.56 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Spooner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.